Skip to main content

07-06-2019 | Oncology | News | Article

ASCO 2019

Prolonged survival possible with pembrolizumab in advanced NSCLC

medwireNews: Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer (NSCLC) can achieve long-term survival with pembrolizumab monotherapy.

As reported in a poster at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, 23.2% of the 101 treatment-naïve patients with locally advanced or metastatic NSCLC were alive at 5 years after initiation of pembrolizumab, as were 15.5% of the 449 patients who had received at least one previous line of therapy.

These overall survival (OS) rates compare with a historical rate of 5.5% among individuals who received chemotherapy for distant metastases, said presenting author Edward Garon, from the University of California Los Angeles in the USA, at a press conference.

“The uniformly negative outlook that has been associated with a diagnosis of advanced non-small cell lung cancer is certainly no longer appropriate,” he told the press.

The benefit of pembrolizumab treatment – given at a dose of either 2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks – appeared to be greatest in patients with high PD-L1 expression. Specifically, in the previously treated group, 5-year OS was 25.0% for those with a PD-L1 tumor proportion score (TPS) of at least 50%, while the rates were 12.6% and 3.5% for individuals with a PD-L1 score of 1–49% and less than 1%, respectively.

And among treatment-naïve patients, the 5-year rates were 29.6% and 15.7% for those with a TPS of at least 50% and 1–49%, respectively. As just 12 patients had a PD-L1 TPS below 1%, data were not reported for this subgroup.

Of note, just over three-quarters (76.7%) of the 60 patients who received pembrolizumab for 2 years or more were alive at data cutoff, which was at a median follow-up of 60.6 months. The 5-year OS rates were a comparable 78.6% and 75.8% for the treatment-naïve and previously treated groups, respectively.

The longer follow-up did not reveal any safety concerns, said Garon, noting that “late-onset toxicity, including immune-related toxicity, was rare.”

Seventeen percent of participants experienced an immune-related adverse event (irAE) of any grade, most commonly hypothyroidism, while pneumonitis was the most frequent irAE of grade 3 or higher.

In response to a question from medwireNews about biomarkers for immunotherapy, Garon said that “the best biomarker eventually is going to be a functional one, but that isn’t where we are yet.”

Although PD-L1 as a biomarker has its negatives, “it has persistently shown an ability to pick out patients who do better,” he added.

Garon said that “there is a great deal of interest” in the tumor mutational burden, but although the biomarker has predicted short-term outcomes “reasonably well,” robust results have not been seen for survival.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 June

See also:

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits